NCT03185195 - Phase 1 Absorption Distribution Metabolism and Excretion of AQX-1125 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 22, 2016

Primary Completion Date

January 4, 2017

Study Completion Date

January 4, 2017

Conditions

Healthy Volunteer

Interventions

DRUG

AQX-1125 Oral Tablet

Part 1: Subjects will receive a single oral dose of AQX-1125 followed by \[14C\]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive \[14C\]-AQX-1125 oral solution.

DRUG

[14C]-AQX-1125 IV

Part 1: Subjects will receive a single oral dose of AQX-1125 followed by \[14C\]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive \[14C\]-AQX-1125 oral solution.

DRUG

[14C]-AQX-1125 Oral Solution

Part 1: Subjects will receive a single oral dose of AQX-1125 followed by \[14C\]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive \[14C\]-AQX-1125 oral solution.

Trial Locations (1)

Unknown

Quotient Clinical, Nottingham